

From: [Philip Malinas, M.D.](#)
To: [Pharmacy Services](#)
Subject: Caplyta formulary inclusion meeting 12/9/21
Date: Monday, December 6, 2021 10:48:50 AM

WARNING - This email originated from outside the State of Nevada. Exercise caution when opening attachments or clicking links, especially from unknown senders.

This is a letter of support for including Caplyta in the Medicaid formulary. Caplyta is a novel antipsychotic whose mechanism is not otherwise represented in the formulary. In treating Schizophrenia we need every possible treatment in order to help these severely mentally ill patients.

In addition, Caplyta is about to be approved for treatment of Bipolar Disorder which will offer an additional, new therapy for these patients as well.

These two disorders represent a large proportion of mentally ill patients that end up hospitalized, jailed or unemployed. Having every possible type of effective treatment for them at our disposal helps to prevent some of these poor outcomes.

Sincerely,

Philip Malinas, M.D.
Board-certified Psychiatrist